Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc is a biotechnology company that develops small molecule therapies to treat diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Fulcrum Therapeutics' stock with a target price of $15, indicating growth potential.
Financial Health
Fulcrum Therapeutics is generating moderate revenue and cash flow, but financial performance shows room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FULC
Hematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: August 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Upcoming clinical readouts and regulatory milestones can create sharp share moves, though outcomes are binary and may increase volatility.
Mechanism Focus
Fulcrum’s approach targets gene-expression control in genetically defined conditions — scientifically promising but dependent on clinical validation.
Rare Disease Market
Treating rare disorders like FSHD can offer meaningful commercial opportunity if approved, yet patient populations and reimbursement dynamics are specialised.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
